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Purpose: The purpose of this study was to identify the underlying molecular genetic defect in a large consanguineous
Pakistani family with Oguchi disease who had been given a diagnosis of autosomal recessive retinitis pigmentosa.
Methods: The family was genotyped with the Affymetrix 10K single nucleotide polymorphism array. Fine-mapping of
a common homozygous region on chromosome 13q was performed using fluorescent microsatellite markers. Mutation
analysis was done by direct sequencing of the candidate gene GRK1 located in the region. The segregation of a novel
mutation in the family and the frequency of the identified mutation in the Pakistani population were determined by StuI
RFLP analysis.
Results: Genetic mapping supported the diagnosis of typical Oguchi disease in a Pakistani family and also resulted in the
identification of a novel nonsense mutation (c.614C>A; p.S205X) in exon 1 of GRK1. This mutation is predicted to result
in premature termination of the protein product, thereby affecting the phototransduction cascade. A clinical reappraisal
of the family revealed that all patients homozygous for this variant had Oguchi disease.
Conclusions: This is the first report to describe a mutation causing typical Oguchi disease in a large consanguineous
Pakistani family. This mutation segregated in eight affected members.
Oguchi disease is a rare autosomal recessive form of
congenital stationary night blindness associated with fundus
discoloration and abnormally slow dark adaptation after light
exposure,  along  with  characteristic  electroretinographic
(ERG)  abnormalities.  The  disease  was  first  reported  by
Oguchi in 1907 as a variant form of congenital stationary night
blindness (CSNB) and was later characterized phenotypically
by  Mizuo  in  1913  [1],  who  demonstrated  the  Mizuo-
Nakamura phenomenon in affected individuals. In this test
after 2–3 h of dark adaptation of the eyes, the diffused yellow
or grey discoloration of the fundus returns to normal, along
with the reappearance of rod function. The discoloration of
the fundus reappears shortly after reexposure to light [2,3].
Oguchi disease has been shown to be more common in the
Japanese population compared to other populations [4]. In
addition to the typical Oguchi disease, variant forms have also
been  reported  without  the  typical  Mizuo-Nakamura
phenomenon  and  variable  fundus  appearances  and  ERG
patterns [5].
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The  first  Oguchi  locus  was  located  on  chromosome
2q37.1 by Maw et al. [6]. Subsequently, mutations in the
arrestin, or S-antigen, gene (SAG) were found to be associated
with  Oguchi  disease.  Later,  a  mutation  in  a  G-protein-
dependent receptor kinase 1 (GRK1), also called rhodopsin
kinase, which is located on chromosome 13q34, was shown
to result in the Oguchi phenotype [7]. The proteins encoded
by these two genes are members of the phototransduction
pathway in rod photoreceptor cells [4,7]. Here, rhodopsin
kinase (RK) and SAG work sequentially in deactivating the
photoactivated  rhodopsin,  thereby  stopping  the
phototransduction cascade.
Rhodopsin kinase is a rod-specific cytosolic enzyme, and
its kinase activity is specifically directed to photoactivated
rhodopsin by phosphorylating multiple serine residues [8].
Various types of mutations, e.g. both missense and protein
truncating, have been shown to result in a decrease in the
catalytic  activity  of  the  protein,  leading  to  delayed
photoreceptor  recovery.  These  mutations  are  mainly
associated with Oguchi disease [7,9,10], although one report
describes the association of GRK1 mutations with retinitis
pigmentosa (RP) [11].
In this paper, we report a novel nonsense mutation in
GRK1  in  affected  members  of  a  large  consanguineous
Pakistani family. These patients initially were diagnosed with
RP. After identifying the genetic defect in affected family
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1788members,  they  were  clinically  re-evaluated  through  dark
adaptation testing. The affected individuals were diagnosed
with typical Oguchi disease, a phenotype that has thus far not
been described in the Pakistani population.
METHODS
Clinical evaluations: Twenty-two individuals from family
RP19, including seven females and 15 males ranging in age
from three to 66 years, were ascertained from the central
region of Punjab province of Pakistan. The eight affected
members had previously been diagnosed by a local doctor
with autosomal recessive RP based on their night blindness.
Ninety-three healthy individuals (26 females, 67 males, age
13–60  years)  some  from  central  Punjab  and  most  from
different regions of Pakistan, were interviewed to exclude the
presence of RP or any other eye disease. Blood samples were
collected from 22 individuals (eight affected and 14 healthy
individuals) from a five-generation pedigree (Figure 1) who
all consented to participate in the study. In two branches (IV6/
IV7, IV8/IV9, and their children) the parents are first cousins.
A consanguineous relationship between III-1 and III-2 is not
known, although they belong to the same community. The
medical and family history of the participants was then taken
through a questionnaire. Fundoscopy without dark adaptation
test  and  ERG  were  performed  that  didn’t  give  clear
characteristics  of  Oguchi  disease.  Fundoscopy  and
electroretinographic (ERG) diagnostic tests were performed
for selected members (IV-3, V-1, and V-2) of the RP19 family.
This study was approved by the Shifa College of Medicine/
Shifa International Hospital Ethics Committee/Institutional
Review Board.
Before the ERG measurements were made, photoreceptor
cells were first dark adapted (scotopic ERG) for 20–30 min to
measure  the  rod  response.  Next,  the  patients  were  light
adapted  for  10  min  (photopic  ERG)  to  measure  the  cone
response. The total (or aggregate) electrical response of the
retina was then recorded with a contact lens electrode using
commercial ERG equipment (LKC Inc., Gaithersburg, MD)
[12].
To confirm the diagnosis of Oguchi disease in this family,
individuals  IV-3,  V-1,  and  V-2  were  studied  by  a  dark
adaptation test of 2–3 h to observe the changes in the fundus
before and after the onset of light exposure. The fundi were
examined by an indirect ophthalmoscope and 20 diopter lens.
The light intensity of the indirect ophthalmoscope was kept at
the lower levels to gain more time to observe the changes in
the retina.
Molecular genetic studies: Blood samples were drawn using
vacutainer  tubes  containing  acid  citrate  dextrose  (Becton
Dickinson product no 364606, Franklin Lakes, NJ). DNA
isolation  was  performed  by  Sambrook’s  method  (organic
method) of DNA extraction using 4 ml of blood, as described
previously [13]. Six affected members from the fourth and
fifth generation (IV-1, IV-2, IV-3, V-9, V-10, V-11) of the
family (Figure 1) were genotyped with the Affymetrix 10K
Figure 1. RP19 pedigree and 13q32.3-
qter haplotypes. White circles represent
healthy females, filled circles represent
affected  females,  white  squares
represent  healthy  males,  and  filled
squares  are  affected  males.  Slashed
symbols indicate deceased individuals.
Arrowhead  marks  the  position  of  the
GRK1  gene  at  13q34.  The  genomic
positions (in Mb) of all the markers are
based on UCSC genome working draft
hg18  (March  2006)  and  indicated
between brackets.
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1789single  nucleotide  polymorphism  (SNP)  array  containing
10,204  SNPs  (Affymetrix,  Santa  Clara,  CA).  Multipoint
parametric linkage analysis and LOD score calculations were
performed with the GeneHunter program in the EasyLinkage
software package version 5.02 [14] using the Decode Genetics
SNP map and the Asian allele frequencies. An autosomal
recessive  mode  of  inheritance  with  full  penetrance  was
assumed, and the disease allele frequency was estimated at
0.001. Fine-mapping of the linkage interval on chromosome
13q was performed with fluorescently labeled microsatellite
markers. These markers were amplified by the polymerase
chain reaction (PCR) under standard PCR conditions, and the
haplotypes were constructed based upon the allele sizes of the
microsatellites. Positions of the microsatellite markers were
derived  from  the  Marshfield  map.  Two-point  parametric
linkage  analysis  and  LOD  score  calculations  of  the
microsatellite  markers  were  performed  by  using  the
SuperLink package version 1.6 in the EasyLinkage software
package.
Sequencing primers for GRK1, a candidate gene in the
region, were as previously reported by Zhang et al. [5]. These
were used to amplify all exons of GRK1 in one of the affected
individuals from each branch of the family, along with a
control sample. The amplified PCR products were separated
on  agarose  gel  and  purified  with  the  Nucleospin  DNA
extraction kit (Nucleospin Extract II, Macherey-Nagel GmbH
&  Co,  Duren,  Germany).  Purified  products  were  directly
sequenced  using  the  corresponding  primers  and  dye-
termination chemistry (BigDye Terminator, version 3 on a
3730 or 2100 DNA analyzer; Applied Biosystems, Foster
City, CA).
To determine the presence of the mutation identified in
GRK1, we amplified exon 1 of this gene in all the family
members of family RP19, 42 unrelated Pakistani probands
with RP, and a panel of 93 Pakistani control individuals. The
552 bp fragment was then digested with the restriction enzyme
StuI, and resolved on an agarose (1.5%) gel. PCR products
with the GRK1 mutation were digested into fragments of 186
and 366 bp.
RESULTS
Family RP19 was initially given a diagnosis of autosomal
recessive RP. However, during fundoscopy of the individuals
IV-3 and V-1, no bone spicule deposits were observed in the
fundus (Figure 2A), which are typical for RP. Scotopic ERG
showed a significantly reduced rod response (data not shown).
Six affected family members were analyzed by whole-
genome SNP analysis, which showed homozygosity for a 15.2
Mb region on chromosome 13q34 between SNPs rs1927724
and  rs723395  with  a  maximum  LOD  score  of  3.29.  The
segregation  of  the  haplotype  among  all  available  family
members was confirmed and expanded by the fluorescently
labeled  microsatellite  markers  between  rs1927724  and
rs723395. In this way, the critical region was refined to a 5-
Mb region between D13S1315 (position 109.1 Mb) at the
centromeric side and 13qter (position 114.1 Mb). All eight
affected individuals were homozygous for this chromosomal
interval (Figure 1). At the telomeric side, no recombinations
were observed between the Oguchi phenotype and the most
telomeric analyzed SNP, rs723395. At the centromeric side,
a  recombination  between  D13S1315  and  D13S1295  was
deduced  between  the  at  risk  haplotypes  in  the  unaffected
individuals  III-1  or  III-2  and  IV-5.  In  addition,  affected
individuals V-9 and V-10 show a paternal at risk haplotype
between D13S1315 and 13qter. We observed a maximum
two-point LOD score of 5.1 for marker D13S1295 at theta 0.
Figure 2. Fundus photographs of patient V-1 who has Oguchi disease.
A: Fundus photograph of individual V-1 with Oguchi disease before
dark  adaptation.  The  gray  discoloration  of  the  fundus  is  a
characteristic sign of Oguchi disease. B: Fundus photograph after 2
h of dark adaptation shows normal appearance of the retina.
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1790One of the genes residing in the homozygous interval was
GRK1 (at 113.3 Mb), in which mutations have been reported
[10] to cause Oguchi disease. All seven coding exons and
flanking  intronic  sequences  of  GRK1  were  sequenced  in
affected family members IV-1, V-5, and V-11. Sequencing
revealed a homozygous change of nucleotide C>A at position
614 in exon 1 of the GRK1 gene in these three patients. This
nucleotide change results in a nonsense mutation, p.S205X
(Figure 3A).
The novel mutation c.614C>A results in the creation of a
restriction site for the StuI restriction enzyme. To determine
the segregation of the mutation, we performed StuI restriction
analysis in all family members, which showed that all parents,
as  well  as  several  unaffected  siblings,  were  heterozygous
carriers of the mutation. Eight unaffected individuals were
found to be homozygous for the wild-type sequence (Figure
3B). As expected, all affected individuals were homozygous
for the mutation. No carriers of the c.614C>A variant were
detected after mutation screening of 42 RP probands and 93
Pakistani controls.
Because mutations in GRK1 are mainly associated with
Oguchi disease, clinical characteristics of the affected family
members were reevaluated. Patients of family RP19 turned
out  to  have  an  Oguchi  phenotype,  since  the  affected
individuals have congenital stationary night blindness and
grey discoloration of the fundus, which are characteristic signs
of the disease. The typical Mizuo-Nakamura phenomenon of
fundus  changes  for  Oguchi  was  observed  in  the  affected
individuals who were subjected to a dark adaptation of only 2
h. The normal recommended time of dark adaptation is at least
2–3 h to see a clear difference between the light and dark
adapted fundus. The Mizuo-Nakamura phenomenon in the
participants  of  our  study  exhibited  a  less  marked
disappearance of the fundus' unusual gray discoloration and
the appearance of the reddish coloration due to reduced time
for dark adaptation (Figure 2B).
DISCUSSION
In  this  study,  we  present  a  Pakistani  family  (RP19)  with
Oguchi disease in whom we found a causative novel protein-
truncating  mutation  in  the  GRK1  gene  (p.S205X).  The
affected members have congenital stationary night blindness
along with diffuse gray discoloration of the fundus and show
the Mizuo-Nakamura phenomenon after dark adaptation of 2
h. ERG data showed nonrecordable rod responses, which is
characteristic for patients affected with Oguchi disease [15].
The Mizuo-Nikamura phenomenon is known to be a specific
sign  of  Oguchi  disease,  an  unusual  form  of  congenital
stationary night blindness, but has also been described in X-
linked  recessive  and  dominant  cone  dystrophy,  Stargardt
disease, and X-linked retinoschisis [16-19].
In the Japanese and European population, several cases
have been reported in which the causative mutations are either
in the SAG gene, or in the GRK1 gene [20-22]. Oguchi disease
is rare worldwide, while the prevalence is the highest in the
Japanese population [23]. A variant form of Oguchi disease
has also been reported to be caused by a deletion in exon 3 of
the  GRK1  gene  without  the  typical  Mizuo-Nakamura
phenomenon in the affected individual [5].
The GRK1 gene encodes rhodopsin kinase, a cytosolic
enzyme  that  belongs  to  the  family  of  signal-transduction
proteins  and  mediates  cellular  responses  in  the  rod
photoreceptor  cells.  It  is  a  serine-threonine  kinase,  which
plays a key role in normal deactivation and recovery of the
photoreceptor  after  exposure  to  light  [9].  In  the  retina,
desensitization  of  rod  cells  occurs  when  light-activated
Figure 3. Sequence chromatograms and
segregation  analysis  of  the  p.S205X
GRK1  variant.  A:  Sequence
chromatogram  of  part  of  exon  1.
Sequence of normal control sample (left
panel) and an affected individual IV-1
(right  panel)  with  the  homozygous
mutant  sequence  c.614C>A.  B:  StuI
restriction analysis of the 552 bp PCR
products  of  exon  1  in  all  family
members. Fragments were resolved on
an 1.5% agarose gel. Individuals with a
single  fragment  of  552  bp  were
identified as homozygous normal since
they did not contain the restriction site
for  StuI.  Those  with  three  fragments
(552  bp,  366  bp,  and  186  bp)  were
heterozygous carriers of the mutation,
and those with two fragments (366 bp
and  186  bp)  carried  the  mutation
homozygously.
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1791rhodopsin is phosphorylated by rhodopsin kinase, followed
by  the  binding  of  visual  arrestin  to  the  phosphorylated
rhodopsin. In turn, this blocks the interaction of rhodopsin
with  transducin,  which  results  in  switching  off  the
phototransduction cascade [24]. As such, rhodopsin kinase is
a crucial factor in regulating the phototransduction cascade
and any defect in its expression is predicted to affect the
normal functioning of the retina.
The work of Choi et al. [25] on Sag/Grk1-deficient mouse
retina  has  demonstrated  the  functional  importance  of
rhodopsin  kinase  in  the  phototransduction  process.  They
showed that when the animals are raised in the dark, they have
normal  retinal  morphology.  However,  when  exposed  to
continuous  light,  these  animals  show  rapid  induction  of
photoreceptor  cell  death  that  appears  to  be  the  result  of
apoptosis. Chen et al. [26] found that the retina of Grk−/− mice
raised in darkness had the same morphology as Grk+/+ mice.
However, constant light exposure of Grk−/− mice resulted in
degeneration,  causing  light-induced  apoptosis  in  the  rods
lacking Grk1.
The  biochemical  effect  of  the  mutations  in  GRK1  in
patients with Oguchi disease has been studied by Khani et al.
[9], who found the compound heterozygous p.V380D and
p.S536fsX6 variants in a European patient. A comparison of
the functional characteristics of the wild-type and these two
mutant  proteins  showed  that  both  mutant  proteins  had
decreased catalytic activity, demonstrating their pathogenic
nature  [9].  In  addition  to  the  GRK1  missense,  null  and
frameshift  mutations  identified  by  different  groups,  many
Oguchi disease patients have been shown to carry deletions
of one or more exons of the gene [4-9]. The novel nonsense
mutation  (p.S205X)  in  GRK1  in  RP19  described  here  is
located in the catalytic protein kinase domain (aa196–219),
and is predicted to result in premature termination of the
protein  product  and  as  such  results  in  a  nonfunctional
rhodopsin kinase.
Our study has resulted in the identification of the first
typical Oguchi family in Pakistan with a novel mutation in
GRK1. This study also demonstrates the power of genetic
studies  to  correctly  diagnose  the  disease.  Previously  this
family was classified as having RP, but our diagnostic clinical
tests and genetic data revealed that this family has Oguchi
disease.
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